BioSenic S.A. : Information on the total number of voting rights and shares
28 Juin 2024 - 7:00AM
BioSenic S.A. : Information on the total number of voting rights
and shares
PRESS RELEASE – REGULATED
INFORMATION
Mont-Saint-Guibert, Belgium, June 28,
2024, 7.00 am CET – BIOSENIC (Euronext
Brussels and Paris: BIOS), the clinical-stage company specializing
in serious autoimmune and inflammatory diseases and cell therapy,
today announces an increase in the total number of voting rights
and shares as a result of the issuance of new shares. The following
information is published in accordance with Article 15 of the
Belgian law of 2 May 2007 on the publication of major shareholdings
in issuers whose shares are admitted to trading on regulated
market.
Total amount of share capital on May 31, 2024 |
EUR 36 650 669 |
Total number of shares with voting rights on May 31, 2024 |
230 724 583 |
Total number of new shares issued between May 31, 2024 and June 28,
2024 |
20 588 234 |
Total amount of share capital on June 28, 2024 |
EUR 37 050 669 |
Total number of shares with voting rights on June 28, 2024 |
251 312 817 |
Total number of voting rights (denominator) on June 28, 2024 |
251 312 817 |
Total number of attributed warrants |
161 556 |
Total number of convertible bonds outstanding |
169 |
Total number of remaining convertible bonds commitments |
0 |
Total number of shares with voting rights that can be issued
following the exercise of the attributed warrants, remaining
convertible bonds commitments and the conversion of the convertible
bonds |
787 136 958 (1) |
(1)
- 161 556 shares could be issued in
case all 161 556 attributed warrants were exercised (excluding the
1 000 000 outstanding warrants which are planned to be cancelled in
accordance with the global restructuring plan which was homologated
by the Enterprise Court on 10 June 2024).
- 91 296 689 shares could be issued
in case all 169 convertible bonds outstanding of the convertible
bonds programs with Global Tech Opportunities 15 were exercised and
converted into shares based on the conversion price of EUR
0.0217423 (95% of the Volume-Weighted-Averaged-Price of BioSenic's
shares on 26 June 2024).
- In the event of full conversion of
the new convertible bonds in accordance with the global
restructuring plan which was homologated by the Enterprise Court on
10 June 2024, 695 678 713 shares could be issued in case all of the
EUR 15.5 million worth of convertible bonds are exercised and
converted into shares based on the conversion price of EUR
0.0222804 (95% of 30-days VWAP on 26 June 2024).
About BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued from its
Medsenic’s arsenic trioxide (ATO) platform. Key target indications
for the autoimmune platform include graft-versus-host-disease
(GvHD), systemic lupus erythematosus (SLE), and now systemic
sclerosis (SSc).Following the merger in October 2022, BioSenic
combined the strategic positionings and strengths of Medsenic and
Bone Therapeutics. The merger specifically enables
Medsenic/Biosenic to develop an entirely new arsenal of various
anti-inflammatory and anti-autoimmune formulations using the
immunomodulatory properties of ATO/oral ATO (OATO).
BioSenic is based in the Louvain-la-Neuve
Science Park in Mont-Saint-Guibert, Belgium. Further information is
available at http://www.biosenic.com.
About the main Medsenic/BioSenic
technology platform
The ATO platform provides
derived active products with immunomodulatory properties and
fundamental effects on the activated cells of the immune system.
One direct application is its use in onco-immunology to treat GvHD
(Graft-versus-Host Disease) in its chronic, established stage.
cGvHD is one of the most common and clinically significant
complications affecting long-term survival of allogeneic
hematopoietic stem cell transplantation (allo-HSCT).
Medsenic has been successful in a phase 2 trial
with its intravenous formulation, Arscimed®, which
has orphan drug designation status by FDA and EMA. The company is
heading towards an international phase 3 confirmatory study, with
its new, IP-protected, OATO formulation. Another selected target is
moderate-to-severe forms of systemic lupus erythematosus (SLE),
using the same oral formulation. ATO has shown good safety and
significant clinical efficacy on several affected organs (skin,
mucosae, and the gastrointestinal tract). Systemic sclerosis is now
full part of the clinical pipeline of Medsenic/BioSenic. This
serious chronic disease badly affects skin, lungs, or
vascularization, and has no current effective treatment.
Preclinical studies on pertinent animal models are positive, giving
good grounds to launch a phase 2 clinical protocol, using new
immunomodulatory formulations of APIs recognized to be active on
the immune system.
The company is currently focusing its present
R&D and clinical activities on a selective, accelerated
development of its autoimmune platform.
Note: The allogeneic cell therapy
platform-originating from the previous listed company Bone
Therapeutics company, may be of renewed interest by using isolated
and purified differentiated bone marrow Mesenchymal Stromal Cells
(MSCs) as a starting material for further isolation of passive or
active biological subcellular elements. Indeed, these cells may
provide new subcellular vesicles potentially able to deliver a
unique and proprietary approach to organ repair. BioSenic is now
involved in determining new patentable approaches in this complex
area of cell therapy.
For further information, please
contact:
BioSenic SAFrançois Rieger, PhD,
CEOTel: +33 (0)671 73 31 59investorrelations@biosenic.com
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the company or, as
appropriate, the company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Biosenic (EU:BIOS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Biosenic (EU:BIOS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024